Sept. 5 (UPI) -- The Food and Drug Administration is cracking down on ingredients from potentially from unverified foreign sources and that could be used in GLP-1 drugs that include Wegovy, Ozembic and Mounjaro.
The drugs are use for treating Type 2 diabetes and, in certain cases, for weight loss.
The FDA announced Friday it published a "green list" of import alert to stop the unverified foreign sources from coming into the U.S. market. Other GLP-1 drugs, some of which are older medications, include Adlyxin, Byetta, Bydureon, Retatrutide, Rybelsus, Saxenda, Trulicity, Victoza, Zepbound.
"This is part of the agency's decisive steps to safeguard consumers from illegal GLP-1 active ingredients imported from overseas to ensure patient safety and a secure drug supply chain," the FDA said in a news release.
Related
